Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento” or the “Company”), announced today that on January 9, 2020, it received a non-binding proposal from a private equity fund to acquire a majority or all of the issued and outstanding shares of the Company for up to $7.00 per share. Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases.
Read the full article: Sorrento Therapeutics, Inc. Received Non-Binding Acquisition Proposal from PE Fund //
Source: https://www.globenewswire.com/news-release/2020/01/10/1968906/0/en/Sorrento-Therapeutics-Inc-Received-Non-Binding-Acquisition-Proposal.html